Format
Sort by
Items per page

Send to

Choose Destination

Best matches for OXYCODONE/PD:

Revisiting Oxycodone Analgesia: A Review and Hypothesis. Ruan X et al. Anesthesiol Clin. (2017)

CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Balyan R et al. Pharmacogenomics. (2017)

Oxycodone physical dependence and its oral self-administration in C57BL/6J mice. Enga RM et al. Eur J Pharmacol. (2016)

Search results

Items: 1 to 20 of 1461

1.
2.

Severe lumbar radiculopathy with epidural venous plexus engorgement in a morbidly obese pediatric patient: A case report.

Jeong HJ, Sim WS, Park HJ, Lee SH, Oh MS, Cho MK, Seon HJ, Lee JY.

Medicine (Baltimore). 2019 Aug;98(33):e16842. doi: 10.1097/MD.0000000000016842.

3.

Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL).

Pan H, Shen P, Shu Q, Lu L, Qian S, Zhou Y, Han F, Guo Q, Yang Z, Pan J, Xu Q, Zhang P, Wang K.

Medicine (Baltimore). 2019 Jun;98(24):e15505. doi: 10.1097/MD.0000000000015505.

4.
5.

Bashing Big Pharma.

Van Way CW 3rd.

Mo Med. 2019 Mar-Apr;116(2):80-82. No abstract available.

6.

An alternating polarity switching assay for quantification of oxycodone and topiramate: An application of LC-MS/MS method in support to PK/PD study in rodents.

Narayanasamy S, Pilli NR, Xu L, Chockalingam A, Shea KI, Stewart S, Patel V, Rouse R, Matta MK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jun 15;1118-1119:93-100. doi: 10.1016/j.jchromb.2019.04.044. Epub 2019 Apr 22.

PMID:
31030106
7.

Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice.

Yang PP, Yeh TK, Loh HH, Law PY, Wang Y, Tao PL.

Eur J Pharmacol. 2019 Jun 5;852:265-273. doi: 10.1016/j.ejphar.2019.04.009. Epub 2019 Apr 6.

PMID:
30959048
8.

Controlled-release opioids cause harm and should be avoided in management of postoperative pain in opioid naïve patients.

Levy N, Mills P.

Br J Anaesth. 2019 Jun;122(6):e86-e90. doi: 10.1016/j.bja.2018.09.005. Epub 2018 Oct 19. No abstract available.

PMID:
30915981
9.

Investigation of Key Genes and Pathways in Inhibition of Oxycodone on Vincristine-Induced Microglia Activation by Using Bioinformatics Analysis.

Liu W, Ye J, Yan H.

Dis Markers. 2019 Feb 10;2019:3521746. doi: 10.1155/2019/3521746. eCollection 2019.

10.

Oxycodone's Unparalleled Addictive Potential: Is it Time for a Moratorium?

Remillard D, Kaye AD, McAnally H.

Curr Pain Headache Rep. 2019 Feb 28;23(2):15. doi: 10.1007/s11916-019-0751-7.

PMID:
30820686
11.

Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea.

Walley AY, Wakeman SE, Eng G.

N Engl J Med. 2019 Feb 21;380(8):772-779. doi: 10.1056/NEJMcpc1816407. No abstract available.

12.

Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain.

Patel J, Lucas CJ, Margalit M, Martin JH.

J Pain Palliat Care Pharmacother. 2018 Jun - Sep;32(2-3):116-123. doi: 10.1080/15360288.2018.1545725. Epub 2019 Feb 8.

PMID:
30735070
13.
14.

A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.

Friedmann N, Marsman MR, de Kater AW, Burns LH, Webster LR.

J Opioid Manag. 2018 Nov/Dec;14(6):437-443. doi: 10.5055/jom.2018.0476.

PMID:
30629280
15.

Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.

Kucera SA, Zamloot MS, Crowley MM, Burns LH, Friedmann N, Barbier R.

J Opioid Manag. 2018 Nov/Dec;14(6):429-436. doi: 10.5055/jom.2018.0475.

PMID:
30629279
16.

The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.

Leppert W, Zajaczkowska R, Wordliczek J.

Expert Opin Pharmacother. 2019 Apr;20(5):511-522. doi: 10.1080/14656566.2018.1561863. Epub 2019 Jan 9. Review.

PMID:
30625013
17.

Standardized nursing and therapeutic effect of oxycontin on oral mucosal pain in nasopharyngeal carcinoma patients.

Hu W, Chen L, Wang C, Guo L, Hua X, Cai Y, Fan Y.

J Cancer Res Ther. 2018;14(7):1594-1599. doi: 10.4103/jcrt.JCRT_551_18.

18.

Oxycodone Exposure: A Magnetic Resonance Imaging Study in Response to Acute and Chronic Oxycodone Treatment in Rats.

Iriah SC, Trivedi M, Kenkel W, Grant SE, Moore K, Yee JR, Madularu D, Kulkarni P, Ferris CF.

Neuroscience. 2019 Feb 1;398:88-101. doi: 10.1016/j.neuroscience.2018.11.042. Epub 2018 Dec 12.

PMID:
30550747
19.

[Relationship of OPRM1 118A/G gene polymorphism and oxycodone analygesic dose in paitents with cancer pain].

Lin T, Li X, Song J, Zhang C, Bie M.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018 Dec 10;35(6):887-890. doi: 10.3760/cma.j.issn.1003-9406.2018.06.027. Chinese.

PMID:
30512171
20.

Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital.

Kim JY, Kim JH, Yee J, Song SJ, Gwak HS.

BMC Geriatr. 2018 Nov 29;18(1):293. doi: 10.1186/s12877-018-0990-1.

Supplemental Content

Loading ...
Support Center